{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:55:57Z","timestamp":1777420557537,"version":"3.51.4"},"reference-count":13,"publisher":"SAGE Publications","issue":"12","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:p>Varenicline (Champix, Chantix) has been available for use in smoking cessation since 2006. This drug has been associated with adverse cardiovascular events. Potential mechanisms for this association include modulation of parasymphathetic output from the brainstem to the heart, release of catecholamines and prothrombotic effect. We report the case of a 30-year-old man with no known cardiac disease, who developed thrombotic occlusion of left anterior descending artery and presented with acute coronary syndrome secondary to treatment with varenicline. The Naranjo probability scale indicates that varenicline was the probable cause of the myocardial infarction.<\/jats:p>","DOI":"10.1177\/1060028013508931","type":"journal-article","created":{"date-parts":[[2014,1,6]],"date-time":"2014-01-06T14:16:10Z","timestamp":1389017770000},"page":"1727-1729","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Varenicline-Induced Coronary Thrombosis"],"prefix":"10.1177","volume":"47","author":[{"given":"Arzu","family":"Kalayc\u0131","sequence":"first","affiliation":[{"name":"Cardiology Department, Kartal Kosuyolu Heart and Research Hospital, Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aysegul","family":"Eren","sequence":"additional","affiliation":[{"name":"Clinic of Chest Diseases, Sureyyapasa Chest Diseases and Chest Surgery Training and Research Hospital, Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gonenc","family":"Kocabay","sequence":"additional","affiliation":[{"name":"Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Can Yucel","family":"Karabay","sequence":"additional","affiliation":[{"name":"Cardiology Department, Kartal Kosuyolu Heart and Research Hospital, Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cetin","family":"Gecmen","sequence":"additional","affiliation":[{"name":"Cardiology Department, Kartal Kosuyolu Heart and Research Hospital, Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cevat","family":"K\u0131rma","sequence":"additional","affiliation":[{"name":"Cardiology Department, Kartal Kosuyolu Heart and Research Hospital, Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2013,11,1]]},"reference":[{"key":"bibr1-1060028013508931","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.869008"},{"key":"bibr2-1060028013508931","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.110218"},{"key":"bibr3-1060028013508931","doi-asserted-by":"publisher","DOI":"10.2165\/11597690-000000000-00000"},{"key":"bibr4-1060028013508931","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e7176"},{"key":"bibr5-1060028013508931","doi-asserted-by":"publisher","DOI":"10.1016\/j.jash.2012.11.003"},{"key":"bibr6-1060028013508931","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2008.01.017"},{"key":"bibr7-1060028013508931","unstructured":"Food and Drug Administration. FDA drug safety communication: safety review update of Chantix (varenicline) and risk of cardiovascular adverse events. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm330367.htm. Accessed October 3, 2013."},{"key":"bibr8-1060028013508931","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.1.47"},{"key":"bibr9-1060028013508931","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.1.56"},{"key":"bibr10-1060028013508931","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.46.4.698"},{"key":"bibr11-1060028013508931","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2013.03.014"},{"key":"bibr12-1060028013508931","unstructured":"Chantix varenicline tablets [product information]. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/021928s012s013lbl.pdf Accessed October 3, 2013."},{"key":"bibr13-1060028013508931","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028013508931","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1060028013508931","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028013508931","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:14:33Z","timestamp":1777374873000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1060028013508931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,1]]},"references-count":13,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["10.1177\/1060028013508931"],"URL":"https:\/\/doi.org\/10.1177\/1060028013508931","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,1]]}}}